# Non-Invasive Evaluation by the HEMOTAG™ Recording Device to Tailor Treatment of Acutely Decompensated Heart Failure

## TL;DR

A wearable device called HEMOTAG was tested to track heart failure treatment progress non-invasively, showing promising results in measuring improvement.

## Contribution

The study introduces a non-invasive wearable device for monitoring heart failure treatment response through cardiac time intervals.

## Key findings

- IVCT measured by HEMOTAG decreased alongside NT-proBNP levels in ADHF patients, indicating treatment effectiveness.
- An IVCT ≥ 40 ms showed high sensitivity and specificity for detecting ADHF.
- HEMOTAG demonstrated feasibility and safety for potential use in remote heart failure management.

## Abstract

This study evaluated the clinical utility of the HEMOTAG™ recording device—A non-invasive, wearable system that measures cardiac time intervals (CTIs)—in managing patients with acutely decompensated heart failure (ADHF). The prospective, single-center study enrolled 105 patients, including those hospitalized with ADHF and a control group with non-HF-related conditions. Daily measurements of isovolumetric contraction time (IVCT), a key CTI marker, were collected using the HEMOTAG device and compared with NT-proBNP levels obtained on admission and day 3. Among ADHF patients, IVCT decreased in parallel with NT-proBNP levels, indicating volume status improvement with therapy. In contrast, the control group showed no significant change in IVCT or NT-proBNP. An IVCT ≥ 40 ms demonstrated strong sensitivity and specificity to detect ADHF (NT-proBNP ≥ 1800 pg/mL). These findings suggest that IVCT trends measured by HEMOTAG correlate with short-term treatment response in ADHF and could offer a non-invasive method to guide heart failure management. The technology demonstrated feasibility, safety, and clinical relevance, supporting its potential role in future remote management strategies.